Phuturdex › Drugs › Aflibercept
Drugs in development · updated 30 October 2026
Aflibercept: clinical trials and development status
Other names and codes: EYLEA Injection, Eylea HD, Enzeevu, Ahzantive, Eydenzelt, Opuviz
As of 30 October 2026 Aflibercept is in 50 active clinical trials (recruiting or ongoing, phases I–III) for 19 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Aflibercept and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Macular degeneration | III | 12 | NCT06864988 |
| Diabetic retinopathy | III | 7 | NCT07705555 |
| Wet Macular Degeneration | III | 6 | NCT06864988 |
| Choroidal neovascularization | III | 4 | NCT05407636 |
| Eye disease | III | 4 | NCT07482176 |
| Blindness | III | 2 | NCT07482176 |
| Macular retinal edema | III | 2 | NCT07705555 |
| Polypoidal choroidal vasculopathy | III | 1 | NCT07389980 |
| Retinal degeneration | III | 1 | NCT05407636 |
| Retinal disease | III | 1 | NCT05407636 |
| Glaucoma | II | 1 | NCT07891182 |
| Retinal vein occlusion | II | 1 | NCT07205887 |
| Uveal melanoma | II | 1 | NCT06121180 |
| Colorectal neoplasm | I | 1 | NCT02298959 |
| Melanoma | I | 1 | NCT02298959 |
| Metastasis | I | 1 | NCT02298959 |
| Ovarian neoplasm | I | 1 | NCT02298959 |
| Renal cell carcinoma | I | 1 | NCT02298959 |
| Sarcoma | I | 1 | NCT02298959 |
Everything on Aflibercept
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.